Daily Brief Health Care: Divi’s Laboratories, Allarity Acquisition, Artrya , Medipal Holdings, Sunshine Biopharma , Vsee Health and more

• 51 companies recorded insider acquisitions in September 2026 — the broadest monthly cohort in recent months.
• We highlight large and small cap companies that experienced significant insider buying during September 2026, as reported on the stock exchanges.
• We also present key sectors which saw insider buying during the month along with names which have moved significantly above/below the insider buying price.

• Allarity Acquisition Corp. is a newly incorporated blank check company formed as a Cayman Islands exempted company. Its purpose is to effect a business combination.
• Allarity Acquisition Corp. is a newly incorporated blank check company seeking an initial business combination, led by an experienced management team. The team is well-positioned to evaluate life sciences opportunities.
• As of May 31, 2026, the company reported total assets of $137,519 and shareholder’s equity of $25,000, but has no operating history and faces going concern risk.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Artrya announced on Friday that it had signed a five-year commercial agreement with SAPPHIRE partner Huntsville Hospital Health System.
• Huntsville is the first SAPPHIRE partner to sign a commercial agreement.
• The market responded positively, with the stock trading as high as $4.20 (+22%) before closing at $3.70 (+7.9%).

• Medipal Holdings (7459 JP) is facing pressure from the UK-based asset management firm, Silchester International to convene an EGM of shareholders. Silchester’s clients are Medipal’s largest shareholders.
• Silchester formally demanded that Medipal convene an EGM to consider four proposals, including dismissal of Director Shuichi Watanabe, partial amendments to the Articles of Incorporation, special dividend, and share buyback.
• Medipal has replaced Shuichi Watanabe and promoted Kuniaki Imagawa as the President and CEO ‘to enhance corporate value and achieve sustainable growth for Medipal under the new management structure.’ 

• Sunshine Biopharma Inc. is a pharmaceutical company researching life-saving medicines in oncology and antivirals, marketing 60 generic prescription drugs, and selling OTC supplements through its Canadian subsidiaries.
• The company markets 60 generic prescription drugs in Canada and is developing K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections.
• The company reported $13,748,301 in cash as of June 30, 2026, with an accumulated deficit of $(77,823,043) and Nasdaq compliance concerns.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Going-Concern Realities: Following its Nasdaq delisting and subsequent move to the OTC market (under ticker VSEED) in August 2026, VSee Health is operating on a month-to-month survival cycle, with a cash balance under $1.0 million and a persistent cash burn that forces reliance on dilutive convertible notes and equity facilities.
• Refocused Strategy: The divestiture of VSee Lab to former Co-CEO Milton Chen in May 2026 was a necessary triage measure to cut $6.0 million in annualized operating expenses and retire 2.87 million shares (representing ~7% of outstanding equity), forcing a singular focus on the high-acuity iDoc Telehealth platform.
• Specious M&A Pivot: The July 2026 non-binding letter of intent (LOI) to acquire a $42.0 million healthcare commerce platform—intended to bring in $35.0 million in annualized revenue and $7.0 million in EBITDA—is a highly speculative bid to diversify cash flows. However, executing this transaction remains highly improbable given the company’s constrained balance sheet and lack of access to institutional capital.